Immuneering Corp Cl A (IMRX) Stock Price, Quote & News

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8080

Website: immuneering.com

Address:

245 Main Street, Second Floor, Cambridge, United States

nyc_doc Sep. 13 at 2:22 AM

$IMRX - In their phase 2a trial - six month survival was 94% for patients treated with a combination of Atebimetnib and mGnP in first-line Pancreatic Cancer Patients. Sadly more than 1/2 the patients died with current standard of care gemcitabine / nab-paclitaxel. They have already have a collaboration with Lilly. Sept 28 they announce their 9 month survival data on Pancreatic Cancer. Pipeline -&gt; Melanoma, Non-Small Cell Lung Ca, and Solid Tumors

1 · Reply

nyc_doc Sep. 12 at 10:53 PM

$IMRX - In their phase 2a trial - six month survival was 94% for patients treated with a combination of Atebimetnib and mGnP in first-line Pancreatic Cancer Patients. Sadly more than 1/2 the patients died with current standard of care gemcitabine / nab-paclitaxel. They have already have a collaboration with Lilly. Sept 28 they announce their 9 month survival data on Pancreatic Cancer. Pipeline -> Melanoma, Non-Small Cell Lung Ca, and Solid Tumors

0 · Reply

WavyTraders Sep. 12 at 8:55 PM

Looks like ALL volume and momentum are shifting in to CMCT! Shorts overextended and now bulls can have them trapped at the bottom. CMCT Could pull a huge multi day run - only 700k float! Don't miss CMCT..,it's breaking out! $SKBL $BITF $VNCE $IMRX news

0 · Reply

dbr_island Sep. 12 at 7:47 PM

$IMRX LFG!!!!!! Haters will say this was post R/S $PLRZ is the next $WLDS I’m telling you 🚨🚨🚨 $OPI $XHG let’s get it

0 · Reply

Jabed206 Sep. 12 at 6:51 PM

$IMRX not going anywhere...

0 · Reply

justme_DC Sep. 11 at 7:01 PM

$IMRX $HIVE Haha, half way there to the "I will never use" a rocket emoji

0 · Reply

buylocellhi Sep. 11 at 2:22 PM

$IMRX gap was filled, and it looks like it wants to run to the HOD!

0 · Reply

buylocellhi Sep. 11 at 2:20 PM

$IMRX the stock price has doubled quite a few times this year, I don’t think it’s done

0 · Reply

Jabed206 Sep. 11 at 1:48 PM

$IMRX https://www.globenewswire.com/news-release/2025/09/10/3148221/0/en/Revolution-Medicines-Shares-New-Clinical-Results-Supporting-Initiation-of-RASolute-303-a-Global-Phase-3-Registrational-Trial-of-Daraxonrasib-in-First-Line-Metastatic-Pancreatic-Duc.html

0 · Reply

ZacksResearch Sep. 11 at 1:30 PM

$IMRX soared 15.5% 🚀 yesterday as investors gear up for updated survival data in pancreatic cancer, set to be announced on Sept. 25 📊 The results could further validate Immuneering’s Deep Cyclic Inhibitors and its potential to transform cancer care 🔬 See what Wall Street analysts recommend 👇 https://www.zacks.com/stock/research/IMRX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-11915&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_11915

0 · Reply

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Aug 26, 2025, 4:05 PM EDT - 19 days ago

Immuneering Announces Closing of $25 Million Private Placement

Aug 25, 2025, 8:00 AM EDT - 20 days ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Aug 21, 2025, 8:00 AM EDT - 24 days ago

Immuneering Announces $25 Million Private Placement

Aug 13, 2025, 4:05 PM EDT - 4 weeks ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 9, 2025, 8:00 AM EDT - 2 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jun 17, 2025, 6:00 AM EDT - 3 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 16, 2025, 8:00 AM EDT - 3 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

May 29, 2025, 8:00 AM EDT - 3 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 4:05 PM EDT - 4 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 2, 2025, 8:00 AM EDT - 5 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 21, 2025, 4:30 PM EDT - 6 months ago

Immuneering Corporation Announces Grant of Inducement Award

Mar 20, 2025, 4:05 PM EDT - 6 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 6 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Feb 3, 2025, 4:05 PM EST - 7 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 7, 2025, 9:28 AM EST - 8 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Dec 19, 2024, 8:00 AM EST - 9 months ago

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 13, 2024, 2:10 PM EST - 9 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Dec 12, 2024, 8:00 AM EST - 9 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Nov 27, 2024, 8:00 AM EST - 10 months ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 10 months ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

May 7, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 19, 2024, 2:19 AM EDT - 1 year ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

Mar 5, 2024, 5:00 PM EST - 1 year ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 8:00 AM EST - 1 year ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 8:00 AM EST - 1 year ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Feb 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Announces Participation in February Investor Conferences

Dec 12, 2023, 8:00 AM EST - 1 year ago

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Nov 20, 2023, 4:05 PM EST - 1 year ago

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 9, 2023, 4:05 PM EST - 2 years ago

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

Oct 4, 2023, 4:05 PM EDT - 2 years ago

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Immuneering to Present at the Morgan Stanley Healthcare Conference

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jul 7, 2023, 5:55 PM EDT - 2 years ago

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

May 30, 2023, 8:00 AM EDT - 2 years ago

Immuneering to Present at the Jefferies Healthcare Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

nyc_doc Sep. 13 at 2:22 AM

1 · Reply

nyc_doc Sep. 12 at 10:53 PM

$IMRX - In their phase 2a trial - six month survival was 94% for patients treated with a combination of Atebimetnib and mGnP in first-line Pancreatic Cancer Patients. Sadly more than 1/2 the patients died with current standard of care gemcitabine / nab-paclitaxel. They have already have a collaboration with Lilly. Sept 28 they announce their 9 month survival data on Pancreatic Cancer. Pipeline -> Melanoma, Non-Small Cell Lung Ca, and Solid Tumors

0 · Reply

WavyTraders Sep. 12 at 8:55 PM

0 · Reply

dbr_island Sep. 12 at 7:47 PM

$IMRX LFG!!!!!! Haters will say this was post R/S $PLRZ is the next $WLDS I’m telling you 🚨🚨🚨 $OPI $XHG let’s get it

0 · Reply

Jabed206 Sep. 12 at 6:51 PM

$IMRX not going anywhere...

0 · Reply

justme_DC Sep. 11 at 7:01 PM

$IMRX $HIVE Haha, half way there to the "I will never use" a rocket emoji

0 · Reply

buylocellhi Sep. 11 at 2:22 PM

$IMRX gap was filled, and it looks like it wants to run to the HOD!

0 · Reply

buylocellhi Sep. 11 at 2:20 PM

$IMRX the stock price has doubled quite a few times this year, I don’t think it’s done

0 · Reply

Jabed206 Sep. 11 at 1:48 PM

0 · Reply

ZacksResearch Sep. 11 at 1:30 PM

0 · Reply

OptimistJP Sep. 11 at 12:48 PM

$IMRX Pullback Day as many will take profits. $9 is the new mark and we will return to this level next week.

0 · Reply

Bgirl_smirk Sep. 11 at 5:47 AM

$IMRX and just like that 2.20 entry and still holding some some things take time 🕰️

0 · Reply

HunterXHunter12 Sep. 11 at 1:34 AM

$IMRX Oppenheimer just updated their target price of IMRX to be $21. Yet so many people are saying it will be 10x. Who s in the wrong ?

0 · Reply

SadyK189 Sep. 11 at 1:22 AM

Top Stocks to watch tomorrow 2 / 3: $AEI $IMRX $VIVS $VNCE $TGL AEI: Initially alerted at 1.94 for 2.4 - 2.65. It went till 2.43 today. Still looking good on daily chart. Key support at 1.8 - 1.95. Next key level to test is 2.7 - 2.9. Currently at 2.33 IMRX: Initially alerted at 5.75 for 6.55 - 7 zone. Currently at 8.45. Still looking good on daily chart. Key support at 6.40 - 6.80. Next key level to test is 9.15 - 9.50. TGL: Good close of 4hours candle. Key support at 1.35 - 1.50. Next key level to test is 2.45 - 2.65. Currently at 2.02 VIVS: Alerted at 2.52 for break of $3. It's at 3.14. Trending nicely on daily chart. Key support at 2.40 - 2.60. Next key level to test is 3.65 - 3.9. It may take sometime though. VNCE: Good close of 4hours candle. Key support at 2.60 - 2.85. Next key level to test is 4.55 - 4.80. However, it can test key support zone as well. Currently at 3.86.

0 · Reply

cholle Sep. 11 at 1:04 AM

$IMRX +24.86%

0 · Reply

OptimistJP Sep. 10 at 11:17 PM

$IMRX On a day with more sells than buys, we still rise by over $1. Good sign. Buy: 1,260,066 Neutral: 631,457 Sell: 1,436,621

0 · Reply

OptimistJP Sep. 10 at 8:46 PM

$IMRX What a wild day. Look at the AH spread: Extended hours $8.46+0.32 (+3.93%) Bid x Size $8.20 x 800 Ask x Size $8.70 x 100 Big sign that shares are scarce. I will hold through the news on the 25th. Lots of swings between now and then but very risky to try to play swing trades. GLTA

0 · Reply

Ranger300 Sep. 10 at 7:15 PM

$CIFR took a hit today, $IMRX was the play but i jumped in too soon on this. still way up last 28 trades though so no problemo, GL bulls

0 · Reply

wealthystar Sep. 10 at 6:17 PM

$IMRX 30+ #hold

0 · Reply

Skyeislimitless Sep. 10 at 6:13 PM

$IMRX MC is only 375m , this could 10x from here if they get FDA approved , IMHO

1 · Reply

CRMDiamondhands Sep. 10 at 6:05 PM

$IMRX ChatGPT: From Phase 2 success to FDA approval, the historical probability is ~15–20%. Oncology: lower, often <10%. With that warning this stock only has a 250M MC. IF, and it's a big if, this drug gets approval then the multiples of increase will be staggering. So risk only what you can stand to lose knowing the odds are still very much against us. Then hang on for the ride.

0 · Reply

uks Sep. 10 at 5:48 PM

$IMRX looks like Private placement getting dumped today, just someone dumped 15K stocks at 8.95 , no inflow so be careful, it will be a sell the news event.

0 · Reply

Market Cap	352.93M
Revenue (ttm)	0.00
Net Income (ttm)	-61.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	858,800
Avg Vol	853,538
Day's Range	N/A - N/A
Shares Out	41.57M
Stochastic %K	79%
Beta	0.43
Analysts	Strong Sell
Price Target	$11.25